Objective: This study was performed to determine the incidence of phyllodes tumor, its pathological sub-types and characteristics in terms of recurrence.

Methodology: This is prospective observational study. This study includes patients of age >40years with breast lump treated in our institute. Study was carried out from 1^stFebruary 2017 to 31^thJanuary 2019. In this study 106 patients were enrolled. Patients’ demographic data, pathology reports and recurrence during 6 month follow up were analyzed.

Results: Breast tumor is common on left side. Out of 106 patients, 94 patients (88.67%) had carcinoma breast, 8 patients (7.5%) had phyllodes tumor and 4 patients (3.77%) had fibroadenoma. Among the phyllodes tumor cases 62.5% tumours were benign, 25 % tumours were borderline, and 12.5 % tumours were malignant. Three patient had local recurrence and one had metastatic disease. Out of these recurrences one was having phyllodes tumor with metastatic disease.

Conclusion: Phyllodes tumours are rare, locally aggressive and mostly benign breast tumors with significant good survival and cure rates.

1. Macdonald OK, Lee CM, Tward JD, et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006; 107: 2127–2133.
2. Parker, SJ and Harries SA. Phyllodes tumours. Postgrad Med J 2001; 77: 428–435.
3. World Health Organization. Histologic Typing of Breast Tumors. 2nd edition. Vol.2. Geneva, Switzerland: WHO; 1981.
4. Reinfuss M, Mitu# s J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996; 77: 910–916.
5. Pandey M, Mathew A, Abraham EK, et al. Primary sarcoma of the breast. J Surg Oncol 2004; 87: 121–125.
6. Fou A, Schnabel FR, Hamele-Bena D, et al. Long-term outcomes of malignant phyllodes tumors patients: an institutional experience. Am J Surg 2006; 192: 492–495.
7. Barth RJ Jr, Wells WA, Mitchell SE, et al. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 2009; 16: 2288–2294.
8. Gnerlich JL, Williams RT, Yao K, et al. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998–2009. Ann Surg Oncol 2014; 21: 1222–1230.
9. Hazem Assi et al. Phyllodes tumors of the breast treated in a tertiary health care center: case series and literature review. Journal of International Medical Research 2018; 0(0) 1–10.
10. Treves N and Sunderland DA. Cystosarcoma phyllodes of the breast: a malignant and a benign tumor; a clinico- pathological study of seventy-seven cases. Cancer 1951; 4: 1286–1332.
11. Norris HJ and Taylor HB. Relationship of histologic features to behavior of cystosar- coma phyllodes. Analysis of ninety-four cases. Cancer 1967; 20: 2090–2099.
12. Azzopardi JG, Ahmed A and Millis RR. Problems in breast pathology. Major Probl Pathol 1979; 11: i-xvi, 1–466.
13. Mitus J, Reinfuss M, Mitu# s JW, et al. Malignant phyllodes tumor of the breast: treatment and prognosis. Breast J 2014; 20: 639–644.
14. Narayanakar RP, Gangaiah DM, Althaf S, et al. Cystosarcoma phyllodes: pathological enigma: a retrospective review of 162 cases. Indian J Cancer 2015; 52: 365–368.
15. Kim S, Kim JY, Kim DH, et al. Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat 2013; 141: 353–363.

Ritesh Dhanbhar